Literature DB >> 2473113

The immune response and the eye. III. Anterior chamber-associated immune deviation can be adoptively transferred by serum.

T A Ferguson1, J D Hayashi, H J Kaplan.   

Abstract

After the anterior chamber (AC) injection of trinitrophenol-coupled (TNP) spleen cells, it is observed that systemic delayed-type hypersensitivity responses to TNP are inhibited by Ag-specific suppressor T cells. We recently reported that suppression is initiated by viable TNP-coupled T cells within the inoculum and upon further analysis we found that these cells have the surface phenotype of CD4+ Ts inducer cells. We report here that treatment of these TNP-T cells with cycloheximide or cytochalasin-B before to AC injection abolishes suppression, whereas treatment with 2000 rad radiation does not. This indicates that protein synthesis and secretion are required to initiate suppression but proliferation is not. Further, we demonstrate the adoptive transfer of suppression by serum of AC inoculated animals. Detection of the component in serum in adoptive transfer assays, however, requires removal of the spleen before AC injection. We establish that the material in serum is a Ts cell product (T suppressor-inducer factor) based on three criteria: it is Ag specific, genetically restricted, and reactive with a mAb that specifically identifies these molecules. These results suggest that the signal leaving the eye to induce suppression of delayed-type hypersensitivity is T cell derived and that molecules mediating immune regulation for this organ are made within the eye and transported via the serum to the spleen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473113

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Armed response: how dying cells influence T-cell functions.

Authors:  Thomas A Ferguson; Jayoung Choi; Douglas R Green
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

3.  Requirement for splenic CD4+ T cells in the immune privilege of the anterior chamber of the eye.

Authors:  M Takahashi; N Ishimaru; K Yanagi; K Saegusa; N Haneji; H Shiota; Y Hayashi
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Evidence for multiple CD95-CD95 ligand interactions in anteriorchamber-associated immune deviation induced by soluble protein antigen.

Authors:  T Kezuka; J W Streilein
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

5.  Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Authors:  Thomas S Griffith; Erik L Brincks; Prajwal Gurung; Tamara A Kucaba; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

6.  CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.

Authors:  P M Stuart; T S Griffith; N Usui; J Pepose; X Yu; T A Ferguson
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

7.  The regulation by light of retinal necrosis and the immune response following anterior chamber inoculation of herpes simplex virus type-1.

Authors:  M Kahn; H J Kaplan; T A Ferguson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 8.  Immunogenic and tolerogenic cell death.

Authors:  Douglas R Green; Thomas Ferguson; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

9.  Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis.

Authors:  Y Gao; J M Herndon; H Zhang; T S Griffith; T A Ferguson
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

10.  Influence of CD8+ T regulatory cells on intraocular tumor development.

Authors:  Kyle C McKenna; Dana M Previte
Journal:  Front Immunol       Date:  2012-09-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.